AFFILIATIONS
1 Medical Student, Tel Aviv University, Tel Aviv, Israel, Sheba Medical Center, Ramat Gan, Israel
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Universitat Autònoma de Barcelona, Barcelona, Spain
3 LMU University Hospital, Munich, Germany
4 Medical Student, Tel Aviv University, Tel Aviv, Israel, Sheba Medical Center, Ramat Gan, Israel
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Complutense University of Madrid, Madrid, Madrid, Spain, Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Medical Student, Tel Aviv University, Tel Aviv, Israel, Sheba Medical Center, Ramat Gan, Israel
12 Medical Student, Tel Aviv University, Tel Aviv, Israel, Sheba Medical Center, Ramat Gan, Israel
13 Medical Student, Tel Aviv University, Tel Aviv, Israel, Sheba Medical Center, Ramat Gan, Israel
14 Medical Student, Tel Aviv University, Tel Aviv, Israel, Sheba Medical Center, Ramat Gan, Israel
15 Medical Student, Tel Aviv University, Tel Aviv, Israel, Sheba Medical Center, Ramat Gan, Israel
16 NYU Langone Health, New York, New York, United States
17 Medical Student, Tel Aviv University, Tel Aviv, Israel, Sheba Medical Center, Ramat Gan, Israel
18 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Weill Cornell Medical College, New York, New York, United States
19 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Weill Cornell Medical College, New York, New York, United States
20 Memorial Sloan Kettering Cancer Center, New York, New York, United States
21 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Weill Cornell Medical College, New York, New York, United States
22 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Weill Cornell Medical College, New York, New York, United States
23 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Weill Cornell Medical College, New York, New York, United States
24 LMU University Hospital, Munich, Germany
25 LMU University Hospital, Munich, Germany
26 Faculty of Health Science, Ben Gurion University of the Negev, Beer Sheva, Israel
27 Rambam Health Care Campus, Haifa, Israel, The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
28 Rambam Health Care Campus, Haifa, Israel, The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
29 Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
30 Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
31 Hackensack University Medical Center, New Jersey, United States
32 Hackensack University Medical Center, New Jersey, United States
33 Medical Student, Tel Aviv University, Tel Aviv, Israel, Sheba Medical Center, Ramat Gan, Israel
34 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Weill Cornell Medical College, New York, New York, United States
35 Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
36 Hackensack University Medical Center, New Jersey, United States
37 LMU University Hospital, Munich, Germany
38 Soroka University Medical center, Beer Sheva, Israel
39 Memorial Sloan Kettering Cancer Center, New York, New York, United States
40 Rambam Health Care Campus, Haifa, Israel, The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
41 Medical Student, Tel Aviv University, Tel Aviv, Israel, Sheba Medical Center, Ramat Gan, Israel
ABSTRACT
Background. Young adults (YA; <40 years) with hematologic malignancies differ from older patients in disease biology, clinical trial representation, and treatment needs. Large B-cell lymphoma (LBCL) in YA skews toward less common subtypes, including primary mediastinal B-cell lymphoma (PMBCL). CD19 CAR T-cell therapy is standard of care for relapsed/refractory LBCL, but most trial and real-world cohorts are dominated by older adults, and outcomes and toxicity patterns specific to YA remain poorly defined.
Methods. This retrospective international multicenter study included patients with LBCL treated with commercial CD19 CAR T-cell therapy between 2016-2026. Patients were categorized as young adults (YA; <40 years), middle-aged adults (40–60 years), or older adults (≥60 years). Overall survival (OS) and progression-free survival (PFS), censored at 24 months, were analyzed using Kaplan–Meier and multivariable Cox models adjusted for performance status, primary refractory disease, prior lines of therapy, pre-lymphodepletion LDH, and CAR T-cell product. Non-relapse mortality (NRM) was estimated using competing-risk methods. Severe cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS) were analyzed using logistic regression adjusted for the same covariates. A biomarker subanalysis was conducted in 477 patients with available pre-infusion inflammatory markers. Prespecified analyses were performed separately in diffuse LBCL/high-grade B-cell lymphoma (DLBCL/HGBCL) and PMBCL, and age-by-product interactions were tested.
Results. Among 1,127 patients, 92 (8%) were YA, 297 (26%) middle-aged, and 738 (66%) older adults. CAR T-cell products included axi-cel (54%), liso-cel (28%), and tisa-cel (17%). Compared with the other age groups, YA had more PMBCL (38% vs 4% vs <1%), primary refractory disease (69% vs 45% vs 35%), and axi-cel use (80% vs 69% vs 45%; all P<0.001), whereas DLBCL NOS accounted for 46%, 79%, and 86%, respectively. GCB disease was present in 44%, 58%, and 46% of YA, middle-aged, and older adults, respectively (P=0.004), while the distribution of prior lines of therapy was similar across age groups (P=0.5). YA (33/477) also demonstrated a less inflammatory baseline phenotype, with lower ferritin, interleukin-6, and tumor necrosis factor-α levels
At 24 months, OS was 70%, 55%, and 57%, while PFS was 51%, 42%, and 42% among patients aged <40, 40–60, and ≥60 years, respectively. NRM was lowest in the YA: 0%, 6.1%, and 8.6% (P=0.025). After multivariable adjustment, patients aged 40–60 years had inferior OS compared with YA (HR 1.77, P=0.02), whereas OS in patients aged ≥60 years was not significantly different (HR 1.50, P=0.08). Age group was not independently associated with PFS among patients aged 40–60 years (HR 1.37,P=0.11) or ≥60 years (HR 1.07, P=0.70), compared with YA.
Grade ≥3 CRS, and ICANS rates did not differ across age groups in unadjusted analyses. After adjusted multivariable analysis, age was not independently associated with grade ≥3 CRS (40–60, p>0.9; ≥60, p=0.30) or grade ≥3 ICANS (40–60, p=0.40; ≥60, p=0.90).
In prespecified histology-specific analyses, age was not independently associated with OS or PFS among patients with DLBCL/HGBCL (n=1037; 47 YA, 276 40–60, and 714 ≥60 years). In contrast, among patients with PMBCL (n=49; 35 YA, 14 40–60 and ≥60 years), age ≥40 years was associated with inferior PFS (HR 4.11, P=0.01) but not OS (HR 5.36, P=0.07).
No significant age-by-product interaction was observed for OS or PFS (P-interaction=0.34 and 0.10, respectively). For any-grade CRS, liso-cel and tisa-cel were associated with lower odds than axi-cel across all age groups, although the magnitude of these differences varied by age, particularly for liso-cel (OR vs axi-cel: 0.13 in YA, 0.32 in 40–60, and 0.08 in ≥60 years; P-interaction=0.02). No interaction was observed for any-grade ICANS (P-interaction=0.52).
Conclusions. YA with LBCL exhibit a distinct clinical phenotype, including PMBCL enrichment and a less inflammatory baseline profile. Age was not independently associated with PFS or severe toxicity, and CAR T-cell product efficacy was consistent across age groups, although product-related differences in any-grade CRS varied by age. Age remained prognostic in PMBCL. These findings support disease biology and treatment characteristics, rather than age alone, as the main determinants of outcomes after CD19 CAR T-cell therapy.